secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K/A
Filed at:   2022-09-27T23:59:59+00:00
Accession:  0001628280-22-025553
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus files CartiHeal audited financials: 2021 net loss $10.2M, zero revenue
--------------------------------------------------------------------------------

- CartiHeal had $0 revenue in 2021; net loss $10.2M; accumulated deficit $67.7M.
- R&D expenses $7.8M; cash and equivalents $4.9M at Dec 31, 2021.
- Acquisition closed July 12, 2022 for ~$315M upfront plus up to $135M in sales milestones.
- Unaudited pro forma combined financials reflect acquisition for six months ended July 2, 2022 and FY 2021.
- CartiHeal's Agili-C implant received FDA PMA in March 2022; pre-launch inventory provision of $642K reversed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022025553/0001628280-22-025553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022025553/bvs-20220712.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-025553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer